Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 8
2012 15
2013 6
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Predicting brain activity using a Bayesian spatial model.
Derado G, Bowman FD, Zhang L; Alzheimer's Disease Neuroimaging Initiative Investigators. Derado G, et al. Stat Methods Med Res. 2013 Aug;22(4):382-97. doi: 10.1177/0962280212448972. Epub 2012 Jun 28. Stat Methods Med Res. 2013. PMID: 22743280 Free PMC article.
Confirmatory factor analysis of the ADNI Neuropsychological Battery.
Park LQ, Gross AL, McLaren DG, Pa J, Johnson JK, Mitchell M, Manly JJ; Alzheimer’s Disease Neuroimaging Initiative. Park LQ, et al. Brain Imaging Behav. 2012 Dec;6(4):528-39. doi: 10.1007/s11682-012-9190-3. Brain Imaging Behav. 2012. PMID: 22777078 Free PMC article.
Genetic architecture of resilience of executive functioning.
Mukherjee S, Kim S, Gibbons LE, Nho K, Risacher SL, Glymour MM, Habeck C, Lee GJ, Mormino E, Ertekin-Taner N, Montine TJ, Decarli C, Saykin AJ, Crane PK; Alzheimer’s Disease Neuroimaging Initiative. Mukherjee S, et al. Brain Imaging Behav. 2012 Dec;6(4):621-33. doi: 10.1007/s11682-012-9184-1. Brain Imaging Behav. 2012. PMID: 22711244 Free PMC article.
Cortical signatures of cognition and their relationship to Alzheimer's disease.
Gross AL, Manly JJ, Pa J, Johnson JK, Park LQ, Mitchell MB, Melrose RJ, Inouye SK, McLaren DG; Alzheimer’s Disease Neuroimaging Initiative. Gross AL, et al. Brain Imaging Behav. 2012 Dec;6(4):584-98. doi: 10.1007/s11682-012-9180-5. Brain Imaging Behav. 2012. PMID: 22718430 Free PMC article.
Alzheimer disease biomarkers are associated with body mass index.
Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative. Vidoni ED, et al. Neurology. 2011 Nov 22;77(21):1913-20. doi: 10.1212/WNL.0b013e318238eec1. Neurology. 2011. PMID: 22105948 Free PMC article.
Citalopram for agitation in Alzheimer's disease: design and methods.
Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group. Drye LT, et al. Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1. Alzheimers Dement. 2012. PMID: 22301195 Free PMC article. Clinical Trial.
Plasma based markers of [11C] PiB-PET brain amyloid burden.
Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, Pike I, Ward M, Johnston C, Lupton MK, Lunnon K, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Mecocci P, Lovestone S, Newhouse S, Dobson R; Alzheimers Disease Neuroimaging Initiative. Kiddle SJ, et al. PLoS One. 2012;7(9):e44260. doi: 10.1371/journal.pone.0044260. Epub 2012 Sep 24. PLoS One. 2012. PMID: 23028511 Free PMC article.
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC; GERAD Consortium; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC); Goate AM. Cruchaga C, et al. Neuron. 2013 Apr 24;78(2):256-68. doi: 10.1016/j.neuron.2013.02.026. Epub 2013 Apr 4. Neuron. 2013. PMID: 23562540 Free PMC article.
Predicting MCI outcome with clinically available MRI and CSF biomarkers.
Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative. Heister D, et al. Neurology. 2011 Oct 25;77(17):1619-28. doi: 10.1212/WNL.0b013e3182343314. Epub 2011 Oct 12. Neurology. 2011. PMID: 21998317 Free PMC article.
30 results